Orion Group Financial Statement Release January–December 2025
View original at globenewswire.comOrion Group Financial Statement Release January–December 2025 ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2025 12 FEBRUARY 2026 at 12:00 EET Orion Group Financial Statement Release January–December 2025 October–December 2025 Highlights Net sales totalled EUR 695.3 (October–December 2024: 434.4) million Operating…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The outlook for 2026 does not include any material milestone payments
80% confidenceSales and marketing expenses are expected to increase in 2026
80% confidenceR&D costs in 2026 will increase from 2025
80% confidenceAnimal Health business division is anticipated to grow slightly in 2026
80% confidenceNubeqa has consistently exceeded expectations, and Orion's annual Nubeqa net sales have the potential to exceed EUR 1 billion by the end of the current decade
80% confidenceTotal capital expenditure in 2026 is not expected to have significant changes compared to 2025
80% confidenceNubeqa royalties and product sales booked by Orion will increase clearly in 2026
80% confidenceExpecting another very strong year in 2026 with continued determined work to build well-being and Orion's future
80% confidenceOrion aims to expand the ODM-212 phase 2 program during 2026
80% confidenceODM-212 has a lot of potential with its mode of action in various indications beyond rare cancers
80% confidenceOrion delivered a very strong performance in 2025 with solid financial results and clear progress in executing strategy
80% confidenceBranded Products business division is estimated to grow in 2026, driven by Respiratory therapy area and Easyhaler portfolio
80% confidence